HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions

Mehlhorn G, Hautmann SK, Koch M, Strehl JD, Hartmann A, Hilfrich R, Beckmann M, Griesser H (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Anticancer Research International Institute of Anticancer Research (IIAR)

Publisher: International Institute of Anticancer Research (IIAR)

Book Volume: 34

Pages Range: 5127-32

Journal Issue: 9

Abstract

The present study was aimed at clarifying if use of a rapid human papillomavirus type 16 L1-specific antibody test could be used to improve clinical management of high-risk HPV-positive low-grade squamous intraepithelial lesion (LSIL)/high-grade squamous intraepithelial lesion (HSIL).The study was nested within a prospective study of 801 patients with early dysplastic high-risk HPV-positive lesions to examine the prognostic significance of HPV-L1 protein detection. Serum samples of 87 patients were tested with a rapid HPV16-L1-specific antibody test. The results were correlated with the clinical outcome during 66 months of follow-up.A combined analysis of the 22 antibody-positive women showed that 17 were also L1 protein-positive, and 5 were L1 capsid protein-negative. An HPV-specific immune competence strongly correlates with clinical remission of low-grade squamous intraepithelial lesion (76.6%). For L1 antigen and HPV16-L1 antibody double-positive women, the risk of progression to cervical intraepithelial neoplasia grade 3 was low (5.8%).The rapid anti-HPV16-L1 test could be a promising tool to improve risk assessment and appropriate clinical management of high-risk HPV-positive early dysplastic lesions.

Authors with CRIS profile

Martin Koch Department of Obstetrics and Gynaecology Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde

Involved external institutions

Cytoimmun Diagnostics GmbH DE Germany (DE) Universität zu Köln DE Germany (DE)

How to cite

APA:

Mehlhorn, G., Hautmann, S.K., Koch, M., Strehl, J.D., Hartmann, A., Hilfrich, R.,... Griesser, H. (2014). HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions. Anticancer Research, 34(9), 5127-32.

MLA:

Mehlhorn, Grit, et al. "HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions." Anticancer Research 34.9 (2014): 5127-32.

BibTeX: Download